Literature DB >> 2481822

Structural characterization of CD6: properties of two distinct epitopes involved in T cell activation.

J A Swack1, R M Gangemi, C E Rudd, C Morimoto, S F Schlossman, P L Romain.   

Abstract

Studies from our laboratory have shown that anti-T12, a mAb which recognizes CD6, is a macrophage-dependent mitogen for human T cells and can augment T cell autoreactivity in vitro. To obtain additional information regarding the potential biological role of CD6 we sought to further characterize its biochemical properties. The CD6 molecule on 125I-surface-labeled T cells and by Western blot analysis was a monomer of mol. wt 130,000 under reducing conditions and mol. wt 117,000 under non-reducing conditions, suggesting the presence of intrachain disulfide bonds. The polypeptide contains a protease sensitive site. In activated T cells, the protein was serine phosphorylated. Analysis of biosynthetically labeled CD6 in the presence of tunicamycin revealed a reduction in mol. wt from 130,000 to 100,000, indicating that the polypeptide is extensively N-glycosylated. The mAb, anti-2H1, had been shown to activate T cells in combination with PMA or the anti-T11(3) mAb but, unlike anti-T12, not in the presence of macrophages alone. The present studies demonstrate by sequential immunoprecipitation that these two mAbs recognize the same polypeptide. However, Western blot analysis and indirect immunofluorescence cross-blocking studies demonstrate that the two mAbs recognize different determinants on CD6. Anti-T12 recognizes an epitope that is present only under non-reducing/non-denaturing conditions, while anti-2H1 recognizes an epitope that is also preserved under reducing/denaturing conditions. A direct comparison of activation properties of the mAbs confirmed that anti-T12 was optimally mitogenic in the presence of macrophages but not PMA, while, conversely, anti-2H1 was optimally mitogenic in combination with PMA but not macrophages, suggesting that the differences in epitope specificity may account for the distinct activation properties of each mAb. Taken together, the structural and functional data strongly suggest that the CD6 membrane glycoprotein may function as a physiologically important receptor structure on human T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2481822     DOI: 10.1016/0161-5890(89)90068-0

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  9 in total

1.  Molecular linkage of the mouse CD5 and CD6 genes.

Authors:  O Lecomte; J B Bock; B W Birren; D Vollrath; J R Parnes
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

2.  Simultaneous cross-linking of CD6 and CD28 induces cell proliferation in resting T cells.

Authors:  L M Osorio; M Rottenberg; M Jondal; S C Chow
Journal:  Immunology       Date:  1998-03       Impact factor: 7.397

3.  A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.

Authors:  Pedro C Rodriguez; Roberto Torres-Moya; Gil Reyes; Claudino Molinero; Dinorah Prada; Ana M Lopez; Isabel M Hernandez; Maria V Hernandez; Jose P Martinez; Xochel Hernandez; Angel Casaco; Mayra Ramos; Yisel Avila; Yinet Barrese; Enrique Montero; Patricia Hernandez
Journal:  Results Immunol       Date:  2012-11-21

4.  Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand.

Authors:  M A Bowen; D D Patel; X Li; B Modrell; A R Malacko; W C Wang; H Marquardt; M Neubauer; J M Pesando; U Francke
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

5.  Genomic organization and classification of the bovine WC1 genes and expression by peripheral blood gamma delta T cells.

Authors:  Carolyn T A Herzig; Cynthia L Baldwin
Journal:  BMC Genomics       Date:  2009-04-24       Impact factor: 3.969

6.  The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins.

Authors:  A Aruffo; M B Melnick; P S Linsley; B Seed
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

7.  Tyrosine phosphorylation of CD6 by stimulation of CD3: augmentation by the CD4 and CD2 coreceptors.

Authors:  S Wee; G L Schieven; J M Kirihara; T T Tsu; J A Ledbetter; A Aruffo
Journal:  J Exp Med       Date:  1993-01-01       Impact factor: 14.307

8.  Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells.

Authors:  D D Patel; S F Wee; L P Whichard; M A Bowen; J M Pesando; A Aruffo; B F Haynes
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

9.  Biophysical Characterization of CD6-TCR/CD3 Interplay in T Cells.

Authors:  Marjolein B M Meddens; Svenja F B Mennens; F Burcu Celikkol; Joost Te Riet; Johannes S Kanger; Ben Joosten; J Joris Witsenburg; Roland Brock; Carl G Figdor; Alessandra Cambi
Journal:  Front Immunol       Date:  2018-10-09       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.